Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329401 | 0.89 | KDM4E (0.49) | ADORA1MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL20329240 | 0.87 | KDM4E (0.39) | PTGS2PTGS1MEN1KMT2AKDM4E | |
| SCHEMBL20329857 | 0.86 | KIT (0.43) | PTGS2PTGS1MEN1KMT2AKDM4E | |
| SCHEMBL23915988 | 0.83 | CTSS (0.36) | KDM4EPOLBHSD17B10 | |
| SCHEMBL20329379 | 0.83 | KDM4E (0.51) | MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL20329237 | 0.81 | MAPT (0.44) | MEN1KMT2AKDM4EPOLBHSD17B10 | |
| SCHEMBL21136103 | 0.81 | GAA (0.39) | MEN1KMT2AKDM4EHSD17B10FYN | |
| SCHEMBL23915990 | 0.81 | KDM4E (0.36) | KDM4EPOLBHSD17B10FYN | |
| SCHEMBL20329236 | 0.77 | KCNH2 (0.41) | FYN | |
| SCHEMBL20329239 | 0.77 | DYRK1A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | Bayer Pharma AG (DE) | 2019-06-27 | — | — | US | disclosed |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | Bayer Pharma AG (DE) | 2019-06-27 | — | — | US | disclosed |
| WO-2018114783-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | PTGS2 173/4885PTGS1 105/4885ADORA2A 2795/4885 |
| US-20190194148-A1 | TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES | HNMT, AANAT, CHRNA5 | PTGS2 807/4885PTGS1 514/4885ADORA2A 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.